BTC Health Ltd (BTC, formerly Biotech Capital Limited) is a Pooled Development Fund which makes active investments in businesses that acquire, develop and distribute medical products in Australia and New Zealand. The company is building a group of high-growth businesses which together are focused on providing access to the specialized therapeutics and medical devices from around the world.
BTC Health (ASX: BTC)
- Home
- BTC Health (ASX: BTC)
Here are the latest articles on BTC Health (ASX: BTC)
BTC Health secures $5m ECMO contract with Royal Children’s Hospital for life-saving medtech
September 24, 2024
Following a highly competitive tender process, medical distribution company BTC Health (ASX: BTC) has secured a $5 million contract with the Royal Children’s Hospital (RCH), continuing a run of successes since undertaking a business transformation 12 months ago to diversify its product portfolio. This five-year RCH contract marks the first implementation of the Eurosets ECMOLIFE
BTC Health drives earnings with product diversification to all major hospital operators
August 29, 2024
It turns out that the departure of a significant partner can be a blessing in disguise, as demonstrated by medical distribution company BTC Health (ASX: BTC), which has delivered revenue and earnings growth through a series of measures implemented through FY24 to reduce their reliance on their previously biggest supplier. In April 2023, BTC confirmed
BTC enters the acquires neuro-spinal medical products market with $720k acquisition
September 18, 2023
In 2022, the top five health problems plaguing the Australian population most were cancer, muscle and bone issues, heart diseases, mental health problems plus drug use disorders, and neurological conditions. Together, they made up about 62% of all health problems in the country. Clearly then, the neurological disease prevalence prevents a notable market opportunity—one which
Pharmaxis streamlines operations with $2m sale of Australian distribution rights
July 1, 2021
Having successfully developed a number of drugs through to regulatory approval and commercial sales, Pharmaxis (ASX: PXS) is set to realise a $2 million windfall with the sale of their Australian distribution rights, a move that will focus the Company’s efforts towards their advancing cancer treatment clinical trials. The deal will send the distribution rights
Recent Articles
